The world's biggest supplier of modern drugs for cancer used its London Investor Day on Sept. 5 to provide an update on its recovery from darker days and outline why the Swiss company should again be regarded as the hottest generator of pharmaceutical research and development, and the leader in hi-tech diagnostics, the field that holds the key to the new era of personalized medicine.
“Our strategy remains firmly focused on innovation, on medical differentiation, on driving personalized health care by leveraging our capabilities across...